ESC 365 - Metabolic effects of 14-day oral ketone ester treatment in patients with heart failure with reduced ejection fraction

Open Access

Metabolic effects of 14-day oral ketone ester treatment in patients with heart failure with reduced ejection fraction

Session: Evolving treatment paradigms in heart failure: from SGLT2 inhibition to transthyretin stabilisation and beyond

Topic: Pharmacotherapy

Speaker: Mr K. Berg-Hansen (Aarhus, DK)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Mr Kristoffer Berg-Hansen

Aarhus University Hospital, Aarhus (Denmark)

0 follower

6 more presentations in this session

Implementation of sodium-glucose co-transporter 2 inhibitors use in patients with heart failure across the ejection fraction: data from the Swedish heart failure registry

Speaker: Doctor G. Ferrannini (Stockholm, SE)

Acoramidis improves serum TTR levels in patients with wild-type or variant transthyretin amyloid cardiomyopathy - results from ATTRibute-CM

Speaker: Doctor A. Ducharme (Montreal, CA)

Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis

Speaker: Doctor V. Castiglione (Pisa, IT)

Outcome and disease progression in patients with wild-type transthyretin cardiomyopathy treated with tafamidis

Speaker: Associate Professor A. Cipriani (Padua, IT)

The efficacy and tolerability of finerenone related to the use and dosage of diuretics at baseline in FINEARTS-HF

Speaker: Doctor M. Chimura (Glasgow, GB)

Access the full session

Evolving treatment paradigms in heart failure: from SGLT2 inhibition to transthyretin stabilisation and beyond

Speakers: Mr K. Berg-Hansen, Doctor G. Ferrannini, Doctor A. Ducharme, Doctor V. Castiglione, Associate Professor A. Cipriani...

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources